The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
Clinical Cancer Research, 08/08/2012
Iasonos A et al. – Continual Reassessment Method (CRM) is more robust to toxicity attribution errors compared to the 3+3 since it uses information from all treated patients, leading to a more accurate MTD estimation at the frequency of attribution errors anticipated in phase I clinical trials.



